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Abstract
Background: Obesity is characterized by the accumulation of fat in the liver and other tissues, leading to insulin resistance.
We have previously shown that a specific inhibitor of glucosylceramide synthase, which inhibits the initial step in the
synthesis of glycosphingolipids (GSLs), improved glucose metabolism and decreased hepatic steatosis in both ob/ob and
diet-induced obese (DIO) mice. Here we have determined in the DIO mouse model the efficacy of a related small molecule
compound, Genz-112638, which is currently being evaluated clinically for the treatment of Gaucher disease, a lysosomal
storage disorder.
Methodology/Principal Findings: DIO mice were treated with the Genz-112638 for 12 to 16 weeks by daily oral gavage.
Genz-112638 lowered HbA1c levels and increased glucose tolerance. Whole body adiposity was not affected in normal mice,
but decreased in drug-treated obese mice. Drug treatment also significantly lowered liver triglyceride levels and reduced
the development of hepatic steatosis. We performed hyperinsulinemic-euglycemic clamps on the DIO mice treated with
Genz-112638 and showed that insulin-mediated suppression of hepatic glucose production increased significantly
compared to the placebo treated mice, indicating a marked improvement in hepatic insulin sensitivity.
Conclusions/Significance: These results indicate that GSL inhibition in obese mice primarily results in an increase in insulin
action in the liver, and suggests that GSLs may have an important role in hepatic insulin resistance in conditions of obesity.
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Introduction
The accumulation of visceral fat in obesity instigates several
pathological changes, including chronic low-grade inflammation,
steatosis, and insulin resistance [1,2,3]. These alterations are
closely associated with the development of type 2 diabetes and
non-alcoholic fatty liver disease (NAFLD) [4,5]. With obesity, type
2 diabetes and NAFLD becoming worldwide epidemics, both
preventive and therapeutic measures are needed to address these
major health care burdens.
A major contributing factor to hyperglycemia in type 2 diabetes
is defective regulation of glucose production by the liver [6,7]. In
normal healthy individuals, insulin tightly controls hepatic glucose
production directly by suppressing glycogenolysis and gluconeo-
genesis. Insulin also acts indirectly by inhibiting glucagon secretion
from the pancreas, and by suppressing lipolysis and the release of
free fatty acids from adipose tissue and gluconeogenic precursors
from skeletal muscle, all of which stimulate gluconeogenesis [8]. In
obese and diabetic patients, hepatic steatosis results in a failure of
insulin action and consequently leads to excessive hepatic glucose
production (HGP) and fasting hyperglycemia [6].
We have previously shown that a small molecule inhibitor of
glucosylceramide synthase (GCS), the initial and rate-limiting
enzyme involved in the biosynthesis of gangliosides and other
glycosphingolipids (GSLs), improved glycemic control, decreased
insulin resistance, and inhibited the development of hepatic
steatosis in several animal models of type 2 diabetes [9,10]. Aerts
et al [11] also obtained similar results using an imino-sugar based
inhibitor of GCS. These data pharmacologically validated GSLs
as having an important role in insulin signaling and hepatic
steatosis, confirming the original observation that transgenic
knockout mice lacking ganglioside GM3 and downstream GSLs
are resistant to glucose intolerance caused by a high fat diet (HFD)
[12,13]. It is not known how GSLs are affecting insulin signaling,
although the current hypothesis is that GSLs within lipid rafts
or microdomains may be modulating the activity of various
membrane-associated receptors, including the insulin receptor.
Also unclear is the primary mode of action of our GCS inhibitors.
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affecting glucose metabolism in different tissues, we have
performed hyperinsulinemic-euglycemic clamps in diet-induced
obese (DIO) mice that had been treated with our small molecule
compounds, and used radio-labeled metabolites to determine the
effect of drug treatment on the uptake of glucose into different
tissues.
Genz-112638 (eliglustat tartrate) is a small molecule inhibitor of
glucosylceramide synthase (GCS) that was originally developed for
substrate reduction therapy of Gaucher disease, which is
characterized by the accumulation of glucosylceramide (GL1) in
the lysosomes of affected individuals [14]. In vitro, Genz-112638
exhibits good potency with an IC50 of ,24 nM against GCS
and no detectable inhibition of a-glucosidases, saccharases, or
lysosomal glucocerebrosidase. The compound also has no
inhibitory activity against either neutral or acid ceramidase and
does not alter cellular ceramide levels either in vitro or in vivo. In
rodents, Genz-112638 is rapidly metabolized with a half-life of 15–
45 minutes. When administered to a murine model of Gaucher
disease by daily oral gavage, the compound decreases GL1 levels
in the liver by ,20% at a dose of 75 mg/kg and by ,60% at a
dose of 150 mg/kg [14]. While Genz-112638 is comparable in
activity to Genz-123346, which was used in previous studies
[9,10], Genz-112638 has a more favorable pharmacokinetic and
pharmacodynamic profile for use in humans. In addition, unlike
Genz-123346, Genz-112638 contains a natural ceramide struc-
ture, i.e. an even number of carbons in its acyl chain. Therefore,
Genz-112638 was chosen for use in clinical trials for Gaucher
disease, and it was of interest to also evaluate this compound
preclinically in animal models of type 2 diabetes. The results
suggest that inhibiting GSLs with Genz-112638 partially corrects
the impaired regulation of HGP in obese mice.
Results
Effect of Genz-112638 on liver sphingolipid levels
The short half-life and rapid metabolism of Genz-112638
in rodents necessitates daily or twice daily dosing to achieve
sufficient exposure in tissues over time. We determined that a
dose of 120–125 mg/kg/day was well-tolerated and effectively
lowered GL1 and GM3 levels when administered by daily oral
gavage. A representative study is shown in Fig. 1. Mice fed a high
fat diet (DIO) or normal chow (Lean) were treated with Genz-
112638 at 120 mg/kg/day for 22 weeks. Liver ceramide levels
were unchanged in the drug treated animals, while liver GL1 and
GM3 levels were decreased by approximately 20–30% (Figs. 1A,
B, and D). The unaltered ceramide levels in the animals treated
with Genz-112638 was not unexpected, since the drug does not
block ceramide synthesis. While ceramide could possibly
accumulate due to inhibiting the conversion of ceramide to
GL1 and other GSLs, this was not observed. Liver GL2, which is
expressed at low levels, trended lower but was not decreased
significantly after drug treatment (Fig. 1C). The duration of drug
treatment in Fig. 1 was longer than in subsequent studies, which
was typically 12–16 weeks. However, we have observed that the
decrease in lipid levels stabilizes within one week of dosing, and
further lipid lowering was not observed with longer treatment
(data not shown).
Figure 1. Sphingolipid levels in the livers of DIO mice after treatment with Genz-112638. C57BL/6 mice were fed a normal diet (Lean) or a
HFD (DIO) for 8 weeks. The DIO mice were then treated with Genz-112638 or placebo (water) by twice daily oral gavage (120 mg/kg/day) for 22
weeks, while remaining on the HFD. Sphingolipid levels were determined by high performance liquid chromatography – tandem mass spectrometry
(see Materials and Methods). Data shown as mean 6 SEM (n=6–9 mice per group). *P,0.05, **P,0.01 Genz-112638 DIO vs. Water DIO.
doi:10.1371/journal.pone.0011239.g001
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weight
To evaluate Genz-112638 in the DIO mouse, we placed normal
C57BL/6 mice on the high fat diet (HFD, 45% kcal from fat)
beginning at 5 weeks of age. After 8 weeks on the diet, the mice
were grouped so as to have comparable glucose and insulin levels
and body weights. We then administered either Genz-112638 or
placebo (water) to the mice by daily oral gavage. In the DIO mice,
drug treatment at either 75 or 125 mg/kg/day resulted in a slight
reduction in food consumption compared to the animals treated
with placebo (water)(Fig. 2A). This decrease was significant
(P,0.05), although the difference between the groups became
less at the later timepoints (e.g. weeks 10–12). While there
appeared to be a corresponding small reduction in weight gain in
the drug treated versus water treated animals (Fig. 2B), this
difference was not statistically significant. In the Lean mice, the
weight of food consumed was considerably higher (.30 g/week)
due to the lower caloric density of normal chow, but there was no
substantial difference in food consumption between the drug
treated versus water treated animals (data not shown). The body
weights of the drug versus placebo treated Lean mice were similar
(Fig. 2B). The results indicate that treatment with Genz-112638
did not significantly alter body weight gain in either the DIO or
Lean mice.
Genz-112638 lowered hemoglobin A1c levels and
improved glucose tolerance in DIO mice
We then determined the effect of Genz-112638 on glucose levels
and glucose tolerance in the diet-induce obese (DIO) mouse.
C57BL/6 mice were placed on either the HFD or normal rodent
chow for 8 weeks. The high fat fed (DIO) or chow fed (Lean) mice
were then orally gavaged daily with Genz-112638 at 75 or
125 mg/kg/day for 12 weeks while remaining on their respective
diets. There was no difference in non-fasting glucose levels
between the DIO and Lean mice at the initiation of treatment (0
week time point) when the mice had been on the HFD for only 8
weeks. The DIO mice became mildly hyperglycemic after an
additional 4 weeks on the HFD, and treatment with Genz-112638
resulted in a small but significant decrease in glucose levels
(P,0.01 at both the 75 mg/kg and 125 mg/kg doses after 8 weeks
of treatment)(Fig. 3A). Drug treatment more consistently lowered
hemoglobin A1c (HbA1c) to levels comparable to those of the
Figure 2. Effect of Genz-112638 on A) food consumption and B) body weight. C57BL/6 mice were fed a normal diet (Lean) or a HFD (DIO)
for 8 weeks. The DIO or Lean mice were then treated with Genz-112638 or placebo (water) by daily oral gavage (125 mg/kg/day) for 12 weeks, while
remaining on their respective diets. Data shown as mean 6 SEM (n=7–14 mice per group). *P,0.05 Genz-112638 DIO (both doses) vs. Water DIO,
weeks 0–9. There was no significant difference in body weights between the Water DIO and drug treated groups.
doi:10.1371/journal.pone.0011239.g002
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PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e11239Figure 3. Non-fasting glucose levels, hemoglobin A1c (HbA1c), and glucose tolerance test of DIO mice treated with Genz-112638. A)
DIO mice were treated with Genz-112638 or placebo (water) by daily oral gavage at 75 or 125 mg/kg/day andnon-fastingglucose levels were measured
after 0, 4, and 8 weeks of treatment. B) HbA1c levels after 12 weeks of treatment. C) Glucose tolerance test. DIO mice that had been treated with Genz-
112638 for 10 weeks were fasted overnight and then injected intraperitoneally with glucose (2g/kg) the following morning. Glucose levels were
measured 0, 20, 40, 60, and 120 minutes post-injection. Data shown as mean 6 SEM (n=6–16 mice per group). *P,0.05, **P,0.01 vs. Water DIO.
doi:10.1371/journal.pone.0011239.g003
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effect on HbA1c levels. The DIO mice treated with drug also
exhibited improved glucose tolerance (Fig. 3C). These data are
consistent with what we previously observed with a related
compound (Genz-123346) [9], and confirm that GCS inhibition
improves glycemic control in the DIO mouse model.
Genz-112638 reduced whole body fat mass in DIO mice
As shown in Figure 2B, we observed that the high fat fed mice
treated with Genz-112638 exhibited a small reduction in weight
gain over time. Using proton magnetic spectrometry (
1H-MRS) on
awake, unanesthetized mice, we quantitated whole body lean and
fat mass for mice that had been treated with Genz-112638
(125 mg/kg) or placebo (water) by daily oral gavage for 12 weeks
while on either a normal or HFD. Lean mass was not affected by
drug treatment on either diet (Fig. 4A). However, whole body fat
mass was significantly reduced in the Genz-112638 treated mice
fed the HFD (Fig. 4B).
Genz-112638 decreased hepatic steatosis in DIO mice
We next determined the effect of Genz-112638 on steatosis in
the liver that typically develops in mice given a high-fat diet. The
livers from DIO mice that had been treated with Genz-112638 (75
or 125 mg/kg) for 16 weeks were sectioned and stained with
hematoxylin and eosin or with Oil Red O, which stains neutral
lipids. The livers from the placebo (water) treated animals
contained numerous vacuoles of variable size as well as cells
having a ‘‘foamy’’ appearance (Fig. 5A). In contrast, the livers
from mice treated with Genz-112638 contained significantly fewer
vacuoles and the vacuoles present were often smaller in size
compared to those found in the control livers. The degree of
hepatocellular fatty change was scored on a scale of 0 to 4, with 0
signifying no fatty change and 4 signifying marked change with
large lipid globules in .75% of hepatocytes. Treatment with
Genz-112638 at 125 mg/kg resulted in a significant decrease in
the fatty change score from 3.160.29 to 1.460.18 (P,0.001)
(Fig. 5B). This result was confirmed by morphometric analysis, in
which the fractional vacuole area of the livers from the drug
treated animals was reduced from 0.1560.04 (Water DIO) to
0.05560.01 (125 mg/kg Genz-112638 DIO)(P,0.05). In addi-
tion, we observed a dose-dependent decrease in liver triglyceride
levels (Fig. 3C). These results indicate that Genz-112638 largely
prevented the development of hepatic steatosis caused by high fat
feeding.
Effect of Genz-112638 on whole body and hepatic
glucose metabolism during hyperinsulinemic-euglycemic
clamps in normal and DIO mice
To investigate how Genz-112638 is effecting these changes and
possibly altering whole body or tissue-specific glucose metabolism,
we performed hyperinsulinemic-euglycemic clamps in mice fed
either normal chow or a HFD for 12 weeks plus or minus
treatment with Genz-112638 (125 mg/kg/day). Insulin-stimulated
whole body glucose uptake, which was determined by the ratio of
the [
3H] glucose infusion rate to the specific activity of plasma
glucose during the final 30 minutes of the clamp, was significantly
decreased in the DIO mice (Fig. 6A). Whole body glycolysis, which
was calculated from the rate of increase in plasma
3H2O
concentration during minutes 90–120 of the clamp, was also
impaired in the DIO mice as expected. Treatment with Genz-
112638 did not significantly increase either insulin-stimulated
whole body glucose uptake or whole body glycolysis (Fig. 6A and
B). Although somewhat unexpected, the results indicated that drug
treatment was unable to cause a measurable increase in overall
glucose metabolism, at least at the particular concentration of
insulin used during the clamps. Genz-112638 treatment also did
not improve glucose uptake or glycogen synthesis in skeletal
muscle (data not shown). In accordance with these results, we have
not observed any change in the glycogen content of the liver or
skeletal muscle as a result of drug treatment (Table 1). However,
given the variability in glycogen levels between animals, and the
absence of a difference in glycogen content between the Lean and
DIO tissues, any significant changes in glycogen levels due to drug
treatment was not anticipated.
Treatment with Genz-112638 did result in a modest but
statistically significant increase in the steady-state glucose infusion
rate needed to maintain euglycemia (Fig. 7A). Prior to the insulin
clamp, basal HGP was observed to be higher in both the DIO and
Lean mice that received Genz-112638 (Fig. 7B). After applying the
2.5 mU/kg/min insulin clamp, HGP in the Lean mice was
essentially zero as expected. The clamp HGP in the DIO mice was
only slightly lower than the basal HGP, but decreased to a greater
extent in the drug-treated DIO mice (Fig. 7C). Thus, overall
Genz-112638 markedly increased the percent suppression of HGP
in the high-fat fed mice (Fig. 7D). The results suggest that the basis
by which Genz-112638 improved glycemic control in DIO mice
may be due in part to increased hepatic insulin sensitivity, thereby
improving insulin-mediated suppression of glucose production
from the liver.
Figure 4. Effect of Genz-112638 on A) whole body fat mass,
and B) whole body lean mass. C57BL/6 mice were fed a normal diet
(Lean) or a HFD (DIO) for 8 weeks. The mice were then treated with
Genz-112638 or placebo (water) by daily oral gavage (125 mg/kg/day)
for 12 weeks, while remaining on their respective diets. Fat and lean
mass were measured by proton magnetic resonance spectroscopy (
1H-
MRS) on awake mice. Data shown as mean 6 SEM (n=10 mice per
group). *P,0.05 Genz-112638 DIO vs. Water DIO.
doi:10.1371/journal.pone.0011239.g004
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In these studies we have shown that Genz-112638, an inhibitor
of GSL synthesis, lowered HbA1c levels, improved glucose
tolerance, decreased whole body adiposity and significantly
reduced the development of steatosis in the liver of DIO mice.
These data concur with our previously reported results using a
chemically related GCS inhibitor, Genz-123346 [9,10]. To gain
further insight into the mechanism underlying these observations,
we performed hyperinsulinemic-euglycemic clamps with radioiso-
tope-labeled glucose to determine the effect of drug treatment on
whole body and tissue specific glucose metabolism. High fat
feeding resulted in defects in both whole body and hepatic glucose
metabolism. Genz-112638 improved insulin sensitivity and
significantly increased insulin-stimulated suppression of HGP in
obese mice. The data suggest that augmented hepatic insulin
action may be a primary effect of GSL inhibition in the DIO
mouse.
Analysis of liver sphingolipids showed a trend toward increased
GL1 and GL2 in DIO mice compared to their lean counterparts,
but overall there were no dramatic differences, and ceramide levels
were unchanged. This result is in contrast to the reported highly
elevated levels of ceramide in ob/ob mice compared to normal
mice (.800% increase) and the 20–40% increase in liver ceramide
levels in obese Zucker rats [11,15,16]. Ceramide has been shown
to have a critical role in insulin resistance [17]. Inhibiting serine
palmitoyltransferase, the initial rate-limiting step in sphingolipid
synthesis, with myriocin lowered ceramide levels, improved
glucose tolerance, increased insulin sensitivity, and decreased
hepatic steatosis in diabetic rodent models [16,18]. The much less
severe phenotype of the DIO mouse compared to the genetically-
induced obese animals may account for the absence of increased
ceramide synthesis and accumulation, at least in the liver. Our
data suggest that the hepatic insulin resistance and steatosis that
develops in the DIO mouse is not due to increased hepatic
ceramide. Conversely, the increased insulin sensitivity and
decreased steatosis in the liver after treatment with Genz-112638
is not due to lowering ceramide levels, but rather may be a
consequence of lowering GSL levels. Notably, myriocin has been
shown to decrease not only ceramide but also GSLs, and part of
the phenotypic improvements observed with myriocin may be
partly attributed to the decrease in GSLs rather than just the
decrease in ceramide alone [19].
It remains to be determined whether drug treatment is affecting
the direct or indirect actions of insulin on HGP, or both. Genz-
112638 may directly increase hepatic insulin receptor (IR)
signaling, since GSLs within lipid rafts are known to modulate
the activity of the IR and other membrane associated receptors
[20,21,22]. We and others [9,11] have shown that GCS inhibitors
activate IR autophosphorylation and downstream effectors both in
vitro and in vivo, and recently Bijl et al. [23] have shown improved
hepatic insulin signaling, as evidenced by increased Akt and
mTOR phosphorylation, using the iminosugar-based GCS
inhibitor N-(59-adamantane-19-yl-methoxy)-pentyl-1-deoxynojiri-
mycin (AMP-DNM) in ob/ob mice. In preliminary studies we
have observed an apparent increase in IR activation in the livers of
DIO mice that received Genz-112638 (data not shown), although
the variability between animals and the fact that IR signaling in
Figure 5. Effect of Genz-112638 on hepatic steatosis. DIO mice were treated with Genz-112638 or placebo (water) by daily oral gavage at 75 or
125 mg/kg/day for 16 weeks. A) Representative liver sections stained with hematoxylin and eosin (H&E). B) Fatty change score of the livers (see
Methods). C) Liver triglyceride levels. Data shown as mean 6 SEM (n=6–10 mice per group). **P,0.01 Genz-112638 DIO vs. Water DIO.
doi:10.1371/journal.pone.0011239.g005
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observed in ob/ob mice has precluded us from a definitive result.
Alternatively, one can speculate that Genz-112638 may alter
the known indirect effects of insulin on HGP through actions in
the pancreas, skeletal muscle, or adipose tissue. For example,
Genz-112638 may augment the ability of insulin to inhibit
glucagon secretion from pancreatic a-cells, or enhance the ability
of insulin to inhibit the release of gluconeogenic precursors from
skeletal muscle and non-esterified fatty acids from adipose tissue,
thereby reducing hepatic gluconeogenesis [8]. Previous studies
using both imino-sugar based GCS inhibitors and ceramide-based
inhibitors have demonstrated increased insulin signaling in both
skeletal muscle and adipose tissue of DIO and ob/ob mice [9,24].
The ability of Genz-112638 to decrease whole body adiposity in
DIO mice suggests a role for indirect alterations of HGP through
improvements in overall lipid metabolism. The decrease in fat
mass may be due to an increase in fatty acid oxidation, although
we were not able to observe any increase in energy expenditure or
oxygen consumption when ob/ob mice were treated with a related
GCS inhibitor (Genz-123346, data not shown). The effect of
Genz-112638 on hepatic inflammation also needs to be evaluated.
Despite the presence of steatotic vacuoles, the degree of
inflammation as assessed histologically was considered within the
normal limits of wild type mice and was not affected by drug
treatment. However, we have reported previously a decrease in
TNF-alpha in the livers of ob/ob mice, and reduced ALT levels in
DIO mice treated with Genz-123346 [10]. Overall, it is likely that
Genz-112638 is both having direct and indirect effects on
regulating HGP, and additional studies are needed to better
understand the how lowering GSLs impacts both the liver and
peripheral tissues to regulate hepatic glucose output.
In conclusion, Genz-112638 has been shown to at least partially
address the insulin resistance, excessive glucose production, and
steatosis in the liver that are hallmarks of obesity and type 2
diabetes. While a number of available and prospective therapies
target hepatic dysregulation either directly or indirectly, including
metformin, glucagon-like peptide-1 (GLP-1) analogs, glucagon
receptor antagonists, thiazolidinediones, and enzyme inhibitors of
gluconeogenesis [25], the use of inhibitors of GSL synthesis is
mechanistically quite distinct from these approaches. Therefore,
Genz-112638 or related inhibitors may represent a promising and
unique therapeutic strategy to correct hepatic insulin resistance
and the associated metabolic disorders that result.
Materials and Methods
Animals
Male C57BL/6 mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). Diet-induced obese (DIO) mice
were generated by placing the mice, beginning at 5 weeks of age,
on a high fat diet (45 kcal% fat) (D12451, Research Diets, Inc.,
New Brunswick, NJ) for 8 weeks. Control animals were placed on
normal rodent chow. The mice remained on either the high fat or
chow diet during the drug-treatment phase. Animals were cared
for in an AAALAC accredited facility in accordance with the
guidelines established by the National Research Council.
Administration of drug
Genz-112638 is a small molecule inhibitor of glucosylceramide
synthase and is an analog of 1-phenyl-2-decanoylamino-3-
morpholino-1-propanol (PDMP) [26]. The synthesis, structure,
and in vitro activity of Genz-112638 have been described
previously [14]. Animals were orally gavaged once a day with a
solution of Genz-112638 in water, or water alone (control group).
Measurement of sphingolipid levels
Liver tissue (15–25 mg) was cut and weighed directly into glass
vials. The tissue was homogenized in a methanol extraction buffer
with a hand-held tissue tearor until the tissue was fully dispersed.
The vial was then placed in a water bath sonicator for 10 min,
vortexed briefly, and the homogenate transferred to a 15 mL
centrifuge tube. The tube was centrifuged at 4000 rpm for 5 min
to pellet debris. The supernatant was added to vials containing
dried internal standards and vortexed to help incorporate the
internal standards into solution. Samples were analyzed on a
system consisting of an HTC PAL autosampler (CTC Analytics
Figure 6. Effect of Genz-112638 on whole body glucose
metabolism. Hyperinsulinemic-euglycemic clamps were performed
in normal diet (Lean) or HFD (DIO) fed mice treated with Genz-112638
or placebo (water) by daily oral gavage (125 mg/kg/day) for 12 weeks.
Animals were continuously infused with [
3H]glucose throughout the
clamps. A) Insulin-stimulated whole body glucose uptake, B) Insulin-
stimulated whole body glycolysis. Data shown as mean 6 SEM (n=10
mice per group). #P,0.05 vs. Water Lean, *P,0.05 Genz-112638 DIO
vs. Water DIO.
doi:10.1371/journal.pone.0011239.g006
Table 1. Glycogen content of livers and muscles after
treatment with Genz-112638.
Group
Liver glycogen (mg/g
tissue)
Muscle glycogen (mg/g
tissue)
Water DIO 15.763.1 1.260.2
112638 DIO 16.962.4 1.260.2
Water Lean 10.061.3 1.260.2
C57BL/6 mice that were fed a normal diet (Lean) or a HFD (DIO) were treated as
described in the legend to Fig. 1. Data shown as mean 6 SEM (n=6–9 mice per
group). P.0.05 between all groups.
doi:10.1371/journal.pone.0011239.t001
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mass spectrometer (Applied Biosystems, Foster City, CA). During
analysis, samples were stored at 9uC in the autosampler cool stack.
The HPLC was run in isocratic mode with a normal-phase silica
column, and MS/MS was performed in the MRM (multiple
reaction monitoring) mode.
Blood analysis
Blood samples were collected by either tail vein nick (glucose) or
retroorbital plexus puncture (HbA1c). Non-fasting glucose levels
were measured using an Accu-Chek CompactH Meter (Roche
Diagnostics, Indianapolis, IN). HbA1c levels were measured using
A1cNowH Monitors (Metrika, Inc., Sunnyvale, CA).
Whole body composition
Measurement of whole body fat and lean masses was performed
using a quantitative magnetic resonance body composition analyzer
(BrukerMini-SpecAnalyzer,EchoMedicalSystems,Houston,TX).
Histopathology
Livers were fixed in 10% neutral buffered formalin and
embedded in paraffin. Sections were then stained with hematox-
ylin-eosin. To visualize neutral lipids, livers were frozen in Tissue-
Tek O.C.T. compound (Sakura Finetek USA, Inc., Torrance, CA)
and sections were stained with Oil Red O. The sections were
examined by a board-certified veterinary pathologist and scored on
a scale of 0–4 for the degree of hepatocellular fatty change as
follows: 0, no significant fatty change; 1, minimal fatty change with
minuteOilRedOpositiveglobulesin,50%ofhepatocytes;2,mild
fatty change with small Oil Red O positive globules present in 20–
100% of hepatocytes and with ,10% containing large vacuoles; 3,
moderate fatty change with Oil Red O positive globules of variable
size in .75% of hepatocytes and cytoplasmic detail obscured in
,25% of hepatocytes; 4, marked fatty change with Oil Red O
positive globules of variable size and including many large globules
filling or expanding the cytoplasm of .75% of hepatocytes;
cytoplasmic detail is obscured in .50% of hepatocytes; neutrophil
infiltrates associated with cell rupture and leakage of lipid.
Quantification of hepatic steatosis and triglycerides
Hepatic steatosis was quantitated by morphometric analysis as
described [10]. Briefly, ten to eighteen independent fields were
acquired from each liver section using a microscope set up for bright
field illumination using a 206 objective lens. A program was
assembled and executed using MetaMorph image analysis software
(Molecular Devices, Sunnyvale, CA), which automatically identified
areas of each image occupied by total tissue, foamy cells, and
vacuoles based upon size, color, and optical density. To measure
triglyceride levels, livers were homogenized in water and total lipids
were extracted with methanol:chloroform (4:3.3). The extracted
lipids were dried in glass vials and then resuspended in dimethylsulf-
oxide. Triglycerides were measured using the Serum Triglyceride
Determination kit (TR0100, Sigma-Aldrich, St. Louis, MO).
Hyperinsulinemic-euglycemic clamp
This study was performed at the Yale Mouse Metabolic
Phenotyping Center and all procedures were approved by the Yale
University Animal Care and Use Committee. From a cohort
(n=120) of mice given the high fat diet for 8 weeks, the upper 50%
with respect to body weight and whole body fat mass gain were
initially selected. Of these mice, 24 with the highest glucose and
insulin levels were selected for the study. The 24 DIO mice and 24
Figure 7. Effect of Genz-112638 on hepatic glucose metabolism. Hyperinsulinemic-euglycemic clamps were performed in normal diet (Lean)
or HFD (DIO) fed mice treated with Genz-112638 or placebo (water) by daily oral gavage (125 mg/kg/day) for 12 weeks. Animals were continuously
infused with [
3H]glucose throughout the clamps. A) Steady-state glucose infusion rates, B) Basal HGP, C) Clamp HGP, D) Insulin-mediated percent
suppression of basal HGP. Data shown as mean 6 SEM (n=10 mice per group). #P,0.05 vs. Water Lean, *P,0.05 Genz-112638 DIO vs. Water DIO.
doi:10.1371/journal.pone.0011239.g007
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dailyoralgavage(125 mg/kg)for12weeks,whileremainingontheir
respectivediets.At3–4 days prior tothe dayof the clamp,indwelling
catheters were inserted into the right jugular vein. After an over-
night fast (,15 h), a 2 h hyperinsulinemic-euglycemic clamp was
performed as described previously [27]. Briefly, human insulin
(Humulin, Eli Lilly, Indianapolis, IN) was infused continuously to
raise plasma insulin levels, and glucose was infused at variable rates
to maintain euglycemia. Basal and insulin-stimulated whole body
glucose turnover was estimated with a continuous infusion of D-
[3-
3H]glucose (PerkinElmer Life and Analytical Sciences, Inc.,
Waltham, MA) for 2 h prior to the clamps (0.05 mCi/min) and
throughout the clamps (0.1 mCi/min). Insulin-stimulated whole
body glucose uptake was calculated as the ratio of the [
3H]glucose
infusion rate to the specific activity of the plasma glucose during the
final 30 min. of the clamps. Whole body glycolysis was calculated
from the rate of increase in the concentration of
3H2O in plasma
from minutes 90–120 of the clamps. Insulin-stimulated whole body
glycogen plus lipid synthesis was estimated by subtracting whole
body glycolysis from wholebodyglucoseuptake.Blood samples were
taken before, during, and at the end of the clamps to determine the
concentrations of plasma [
3H]glucose,
3H2O, 2-[
14C]DG and
insulin. At the end of the clamps, tissues were harvested for
biochemical analysis as described previously [28].
Liver and Muscle Glycogen
Tissues were collected and frozen on dry ice and stored at
280uC. 100 mg of liver or muscle was homogenized in 1 mL of
homogenization buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl,
25 mM b-glycerophosphate, 20 mM sodium fluoride, 1 mM
sodium orthovanadate, 2 mM sodium pyrophosphate, 2 mM
EDTA, and Roche Complete protease inhibitor cocktail) using
a TissueLyser II (Qiagen, Valencia, CA). The lysates were
centrifuged at 14,000 rpm for 15 min at 4uC. The supernatants
were aliquoted and stored at 280uC. 3 ml of tissue lysate
supernatant was diluted with 147 ml water and then dried under
vacuum in a Savant speed vac without heat. Trifluoroacetic acid
(200 ml of 4 N) was added and incubated at 100uC for 4 h. The
samples were centrifuged and dried under vacuum without heat.
The dried samples were dissolved in 18 mM 2-deoxy-D-glucose
and then analyzed with HPAE-PAD on a Dionex BioLC with a
CarboPac PA10 column (isocratic elution with 20% 200 mM
NaOH, 80% water) coupled to an ED40 electrochemical detector.
Statistical analysis
Data were analyzed by the one-way ANOVA followed by
Boneferroni’s post-hoc test using the Prism 4 software program
(GraphPad Software, Inc., San Diego, CA). Data were considered
significant if P,0.05.
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